Summary
Aflac Incorporated's 2019 10-K filing reveals a company with robust financial performance, driven primarily by its Japanese operations which accounted for 69% of total revenues. Total revenues reached $22.3 billion, with net earnings of $3.3 billion ($4.43 per diluted share). The company demonstrated strong capital positions, with shareholders' equity growing to $29.0 billion, bolstered by a significant net unrealized gain on investment securities. Aflac returned $2.4 billion to shareholders through share repurchases and dividends in 2019, indicating a commitment to shareholder value. A key area of focus for investors is the impact of the Japan Post Group investigation and related sales suspensions, which led to a material decrease in Aflac Japan's sales through this channel, a trend expected to continue in the near term. Despite this challenge, Aflac Japan's core cancer and medical insurance products remain strong. In the U.S., Aflac acquired Argus Dental & Vision, Inc., aiming to expand its dental and vision offerings. The company continues to navigate a complex regulatory environment and manages significant market risks, including interest rate sensitivity and foreign currency fluctuations, particularly the yen/dollar exchange rate.
Financial Highlights
37 data points| Revenue | $22.31B |
| SG&A Expenses | $3.09B |
| Operating Expenses | $5.92B |
| Operating Income | $4.46B |
| Interest Expense | $228.00M |
| Net Income | $3.30B |
| EPS (Basic) | $4.45 |
| EPS (Diluted) | $4.43 |
| Shares Outstanding (Basic) | 742.41M |
| Shares Outstanding (Diluted) | 746.43M |
Key Highlights
- 1Aflac Japan contributed significantly to total revenues (69%) and total assets (83%) in 2019, highlighting its strategic importance.
- 2Total revenues increased by 2.5% to $22.3 billion, and net earnings rose to $3.3 billion, or $4.43 per diluted share.
- 3Shareholders' equity increased to $29.0 billion, with a substantial net unrealized gain on investment securities of $8.5 billion.
- 4The company returned $2.4 billion to shareholders through share repurchases ($1.6 billion) and dividends ($0.8 billion) in 2019.
- 5Sales in the Japan Post Group channel for Aflac Japan's cancer insurance products saw a material decline starting in August 2019 due to improper sales practices investigations, with expectations of continued weakness in the near term.
- 6Aflac U.S. acquired Argus Holdings, LLC and its subsidiary for $75 million, plus up to $21 million in contingent consideration, to expand its dental and vision product offerings.
- 7The company maintains a strong capital position, with Aflac Japan's Solvency Margin Ratio (SMR) at 1,043% and Aflac's company action level RBC ratio at 539% as of December 31, 2019.